[go: up one dir, main page]

PL1622880T3 - Podstawione dihydrochinazoliny o właściwościach przeciwwirusowych - Google Patents

Podstawione dihydrochinazoliny o właściwościach przeciwwirusowych

Info

Publication number
PL1622880T3
PL1622880T3 PL04728119T PL04728119T PL1622880T3 PL 1622880 T3 PL1622880 T3 PL 1622880T3 PL 04728119 T PL04728119 T PL 04728119T PL 04728119 T PL04728119 T PL 04728119T PL 1622880 T3 PL1622880 T3 PL 1622880T3
Authority
PL
Poland
Prior art keywords
dihydrochinazolines
substituted
antiviral properties
antiviral
properties
Prior art date
Application number
PL04728119T
Other languages
English (en)
Other versions
PL1622880T6 (pl
Inventor
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Thomas Lampe
Susanne Nikolic
Jürgen Reefschläger
Rudolf Schohe-Loop
Frank Süssmeier
Holger Zimmermann
Rolf Grosser
Kerstin Henninger
Guy Hewlett
Jörg Keldenich
Dieter Lang
Peter Nell
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1622880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of PL1622880T3 publication Critical patent/PL1622880T3/pl
Publication of PL1622880T6 publication Critical patent/PL1622880T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04728119T 2003-05-02 2004-04-17 Podstawione dihydrochinazoliny o właściwościach przeciwwirusowych PL1622880T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
EP04728119.1A EP1622880B3 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften
PCT/EP2004/004103 WO2004096778A1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften

Publications (2)

Publication Number Publication Date
PL1622880T3 true PL1622880T3 (pl) 2007-08-31
PL1622880T6 PL1622880T6 (pl) 2018-08-31

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04728119T PL1622880T6 (pl) 2003-05-02 2004-04-17 Podstawione dihydrochinazoliny o właściwościach przeciwwirusowych

Country Status (38)

Country Link
US (4) US7196086B2 (pl)
EP (1) EP1622880B3 (pl)
JP (1) JP4733631B2 (pl)
KR (1) KR100927063B1 (pl)
CN (1) CN100393706C (pl)
AR (1) AR044078A1 (pl)
AT (1) ATE355280T1 (pl)
AU (1) AU2004233978B2 (pl)
BR (1) BRPI0410029B8 (pl)
CA (1) CA2524069C (pl)
CL (1) CL2004000930A1 (pl)
CO (1) CO5700764A2 (pl)
CY (2) CY1106476T1 (pl)
DE (2) DE10319612A1 (pl)
DK (1) DK1622880T6 (pl)
EC (1) ECSP056138A (pl)
EG (1) EG25273A (pl)
ES (1) ES2284007T7 (pl)
FR (1) FR18C1029I2 (pl)
HN (1) HN2004000146A (pl)
HU (2) HUS1800018I1 (pl)
IL (1) IL171513A (pl)
MA (1) MA27794A1 (pl)
MX (1) MXPA05011707A (pl)
MY (1) MY144616A (pl)
NL (1) NL300933I2 (pl)
NO (2) NO333265B3 (pl)
NZ (1) NZ543317A (pl)
PE (1) PE20050145A1 (pl)
PL (1) PL1622880T6 (pl)
PT (1) PT1622880E (pl)
RU (1) RU2360912C2 (pl)
SI (1) SI1622880T1 (pl)
TW (1) TWI335912B (pl)
UA (1) UA82519C2 (pl)
UY (1) UY28294A1 (pl)
WO (1) WO2004096778A1 (pl)
ZA (1) ZA200508710B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PL3010891T3 (pl) * 2013-06-19 2019-11-29 Aicuris Anti Infective Cures Gmbh Amorficzny letermowir i jego stałe preparaty farmaceutyczne do podawania doustnego
US9890128B2 (en) 2013-12-12 2018-02-13 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
US10392353B2 (en) * 2015-11-24 2019-08-27 Merck Sharp & Dohme Corp. Processes for making substituted quinazoline compounds using hydrogen bonding catalysts
CN109476677B (zh) * 2016-08-08 2024-06-07 辉诺生物医药科技（杭州）有限公司 抗hcmv病毒化合物
AU2019218150B2 (en) 2018-02-08 2021-05-13 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
CA3112326A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
WO2021061898A1 (en) 2019-09-26 2021-04-01 Novartis Ag Antiviral pyrazolopyridinone compounds
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
UY39096A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
AR121440A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método de preparación de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, dicho compuesto y el uso del mismo para el tratamiento de infecciones virales
UY39097A (es) * 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acético
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN118974026A (zh) * 2022-04-01 2024-11-15 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
PL351374A1 (en) 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1325008B1 (en) * 2000-07-31 2005-10-05 F. Hoffmann-La Roche Ag Piperazine derivatives
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
JP4480941B2 (ja) 2001-04-19 2010-06-16 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 抗ウイルス剤としての新規アリールスルホンアミド
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) * 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
EP1848698B1 (en) * 2005-01-25 2013-03-13 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
ATE449097T1 (de) * 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
PL3010891T3 (pl) * 2013-06-19 2019-11-29 Aicuris Anti Infective Cures Gmbh Amorficzny letermowir i jego stałe preparaty farmaceutyczne do podawania doustnego

Also Published As

Publication number Publication date
NO333265B1 (no) 2013-04-22
ZA200508710B (en) 2006-12-27
EG25273A (en) 2011-12-04
WO2004096778A1 (de) 2004-11-11
BRPI0410029B1 (pt) 2019-12-31
UY28294A1 (es) 2004-11-30
PT1622880E (pt) 2007-06-04
NO20055649L (no) 2006-01-31
DK1622880T6 (da) 2018-06-18
USRE46791E1 (en) 2018-04-17
CY2018019I1 (el) 2018-12-12
AU2004233978A1 (en) 2004-11-11
KR20060009883A (ko) 2006-02-01
AU2004233978B2 (en) 2010-02-11
EP1622880A1 (de) 2006-02-08
CY1106476T1 (el) 2012-01-25
PE20050145A1 (es) 2005-05-22
HUS1800018I1 (hu) 2018-05-28
SI1622880T1 (sl) 2007-08-31
HK1092463A1 (zh) 2007-02-09
FR18C1029I2 (fr) 2020-07-17
US20050065160A1 (en) 2005-03-24
IL171513A (en) 2011-11-30
ES2284007T7 (es) 2018-06-20
USRE49698E1 (en) 2023-10-17
ES2284007T3 (es) 2007-11-01
MY144616A (en) 2011-10-14
ATE355280T1 (de) 2006-03-15
JP2006525249A (ja) 2006-11-09
EP1622880B1 (de) 2007-02-28
DK1622880T3 (da) 2007-06-25
CA2524069A1 (en) 2004-11-11
RU2005137276A (ru) 2006-07-27
BRPI0410029A (pt) 2006-04-25
CA2524069C (en) 2011-11-08
HN2004000146A (es) 2008-06-24
CN100393706C (zh) 2008-06-11
CL2004000930A1 (es) 2005-03-18
ECSP056138A (es) 2006-04-19
EP1622880B3 (de) 2018-05-23
PL1622880T6 (pl) 2018-08-31
US20070191387A1 (en) 2007-08-16
DE10319612A1 (de) 2004-11-18
JP4733631B2 (ja) 2011-07-27
CO5700764A2 (es) 2006-11-30
US7196086B2 (en) 2007-03-27
TWI335912B (en) 2011-01-11
FR18C1029I1 (pl) 2018-08-17
HUS1800028I1 (hu) 2018-07-30
CN1784390A (zh) 2006-06-07
MA27794A1 (fr) 2006-03-01
NL300933I2 (nl) 2018-04-26
NO333265B3 (no) 2019-06-03
MXPA05011707A (es) 2006-02-13
CY2018019I2 (el) 2018-12-12
TW200510343A (en) 2005-03-16
DE502004003052D1 (de) 2007-04-12
BRPI0410029B8 (pt) 2021-06-15
KR100927063B1 (ko) 2009-11-13
NO20055649D0 (no) 2005-11-30
NZ543317A (en) 2008-05-30
NO2018022I1 (no) 2018-07-04
AR044078A1 (es) 2005-08-24
US8513255B2 (en) 2013-08-20
UA82519C2 (uk) 2008-04-25
RU2360912C2 (ru) 2009-07-10

Similar Documents

Publication Publication Date Title
HUS1800028I1 (hu) Antivirális tulajdonságú szubsztituált dihidrokinazolinok
TWI372050B (en) (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ZA200603879B (en) Substituted indazole-O-glucosides
IL175490A0 (en) Substituted indazole-o-glucosides
EP1680131A4 (en) SUBSTITUTED INDOLE-O-GLUCOSIDES
ZA200603880B (en) Substituted indole-O-glucosides
DE502004011703D1 (en) N-heterocyclyl-phenylsubstituierte cyclische ketoenole
DE602004012071D1 (en) T-hilfe
DE602004020356D1 (en) Phenoxyessigsäurederivate
DE602004030538D1 (en) Präzisionssubstratlagerbehälter
DE502004009243D1 (en) Spirocyclische cyclohexan-derivate
DE502004003476D1 (en) Standfuss
DE602004027010D1 (en) Thermotherapiehülle
DE502004006683D1 (en) Injection-locked-oscillator-schaltkreis
ZA200604331B (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
DE502004011852D1 (en) Nspritzventil
DE502004004146D1 (en) Pyrazolverbindungen
DE112004002769D2 (en) Schienengeführtes transportsystem
DE502004011343D1 (en) Rotorspinnmaschine
DE602004012262D1 (en) Benzimidazolonverbindung
DE602004020525D1 (en) Imidazolderivate
IL172630A0 (en) Substituted spirobenzazepines
GB0318094D0 (en) Novel combination
DE502004012153D1 (en) Rotorspinnmaschine
GB0325291D0 (en) Novel combination